Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as Compared with Chemotherapy Alone By Ogkologos - June 24, 2025 809 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 816 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Experimental CAR T-Cell Therapy Shrinks Tumors in Children with Deadly Brain... January 2, 2025 Signal of Increased Risk of Major Cardiovascular Events and Cancer with... June 21, 2021 German Shepherds Detect Fast-Growing Form Of Breast Cancer And Save Their... February 18, 2020 ESMO Releases New Patient Guide in Hepatocellular Carcinoma June 30, 2020 Load more HOT NEWS FDA Approves Capmatinib for Metastatic NSCLC Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in... Treatment Guided by Comprehensive Genomic Profiling and Expert MTB Decision-Making Improves... Adding Blinatumomab to Consolidation Chemotherapy Improves OS in Adult Patients in...
